DiscoverGRACEcast Lung Cancer VideoCO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

Update: 2014-06-29
Share

Description

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

Comments 
In Channel
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

2014-07-3104:36

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

2014-07-2705:28

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

2014-07-2202:27

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

2014-07-1707:28

Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

2014-07-1307:22

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

2014-07-0803:52

MET-Amplified Lung Cancer: A New Target for XALKORI?

MET-Amplified Lung Cancer: A New Target for XALKORI?

2014-07-0307:18

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

2014-06-2904:10

FGFR and Its Role in Treating Squamous Cell Lung Cancer

FGFR and Its Role in Treating Squamous Cell Lung Cancer

2014-06-2502:21

AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

2014-06-2411:36

What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?

What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?

2014-06-2302:17

The Promise of Immunotherapy in Lung Cancer

The Promise of Immunotherapy in Lung Cancer

2014-06-1801:21

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

2014-06-1808:16

Is Progression-Free Survival Meaningful?

Is Progression-Free Survival Meaningful?

2014-06-1703:25

DDR2 Mutations in Squamous Cell Lung Cancer

DDR2 Mutations in Squamous Cell Lung Cancer

2014-06-1601:07

Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?

Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?

2014-06-1209:26

What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?

What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?

2014-06-1103:50

How Do We Make EGFR Inhibitors Work Better for Patients

How Do We Make EGFR Inhibitors Work Better for Patients

2014-06-0903:15

TH 302: New Drug May Make Tumors Less Resistant to Treatment

TH 302: New Drug May Make Tumors Less Resistant to Treatment

2014-06-0401:26

Should We Do Broad Sequencing of All Lung Tumors?

Should We Do Broad Sequencing of All Lung Tumors?

2014-06-0103:21

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

cancerGRACE - H. Jack West, MD